Literature DB >> 10076781

Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.

C Prantera1, E Berto, M L Scribano, G Falasco.   

Abstract

BACKGROUND AND AIMS: The use of antibiotics in the treatment of active Crohn's disease has recently increased on the assumption that enteral flora may play a role in the origin of symptoms and/or complications of Crohn's disease. The aim of this study was to evaluate retrospectively the efficacy of metronidazole and/or ciprofloxacin in the treatment of acute phases of Crohn's disease.
METHODS: The clinical records of 233 inpatients seen at our clinic for active Crohn's disease and treated with metronidazole and/or ciprofloxacin (1 g daily each) during the period 1984-1996 were reviewed; the patients were divided into three groups according to antibiotic therapy. The primary criterion of success was the achievement of a complete or partial remission evaluated on the basis of the Simple Index; a secondary criterion of success was the efficacy of therapy on individual symptoms and signs.
RESULTS: Similar rates of success were obtained with the three schemes of treatment: 70.6% with antibiotic combination, 72.8% with metronidazole, 69.0% with ciprofloxacin. The most frequent symptoms and signs such as diarrhoea, abdominal pain, fever, abdominal mass and abscesses improved in about 60% of patients in the three groups. Remission time after antibiotic treatment was about one year. Side effects requiring discontinuation of therapy occurred in about 20% of patients.
CONCLUSIONS: Metronidazole and ciprofloxacin seem to be useful in treating active phases of Crohn's disease. These results strongly support the important role of faecal flora in causing Crohn's disease symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10076781

Source DB:  PubMed          Journal:  Ital J Gastroenterol Hepatol        ISSN: 1125-8055


  9 in total

Review 1.  Antibiotic therapy for Crohn's disease: a review.

Authors:  Simon Lal; A Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

Review 2.  Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria.

Authors:  K Hultén; A Almashhrawi; F A El-Zaatari; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

Review 3.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

4.  Meta-analysis of ciprofloxacin in treatment of Crohn's disease.

Authors:  Xiao-Wei Wu; Hong-Zan Ji; Fang-Yu Wang
Journal:  Biomed Rep       Date:  2014-10-01

5.  The Role of Antibiotics in Inflammatory Bowel Disease.

Authors:  Chandrashekhar Thukral; Win J Travassos; Mark A Peppercorn
Journal:  Curr Treat Options Gastroenterol       Date:  2005-06

6.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

Authors:  C Prantera; M L Scribano; G Falasco; A Andreoli; C Luzi
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 7.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

Review 8.  Diagnosis and management of fistulizing Crohn's disease.

Authors:  Ole Haagen Nielsen; Gerhard Rogler; Dieter Hahnloser; Ole Østergaard Thomsen
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-01-20

Review 9.  Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas.

Authors:  Alghalya Khalid Sulaiman Al-Maawali; Phuong Nguyen; P Terry Phang
Journal:  Can J Gastroenterol Hepatol       Date:  2016-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.